Swiss pharmaceutical giant Novartis has agreed to acquire UK-based biotechnology firm Myricx Bio for an upfront payment of USD 1.1 billion and up to USD 400 million in milestones. The transaction integrates Myricx's proprietary NMTi payload technology into Novartis's oncology portfolio to advance targeted treatments for solid tumors.
In a recent strategic announcement, multinational pharmaceutical corporation Novartis confirmed a definitive agreement to purchase Myricx Bio, a privately held UK biotechnology enterprise specializing in advanced cancer therapies. The financial terms stipulate a USD 1.1 billion upfront cash payment from Novartis, accompanied by an additional USD 400 million contingent upon specific development milestones. The acquisition is projected to finalize in the second half of 2026, pending standard regulatory clearances.
This acquisition facilitates the integration of Myricx’s proprietary N-myristoyltransferase inhibitor (NMTi) technology into Novartis’s broader oncology pipeline. Unlike conventional antibody-drug conjugate (ADC) payloads that frequently encounter tumor resistance, NMTi payloads are engineered to disrupt essential enzymatic processes required for cancer cell survival. Myricx currently possesses two lead therapeutic assets targeting B7-H3 and HER2 proteins, which have demonstrated preclinical efficacy against solid tumors that resist standard treatments.
The transaction addresses a critical bottleneck within the global biopharmaceutical sector, where developers are aggressively seeking novel mechanisms to overcome therapeutic resistance in oncology. By securing early access to this differentiated ADC payload class, Novartis reduces its reliance on saturated drug mechanisms and expands its capacity to treat complex malignancies across varied solid tumor settings.
For healthcare investors and competitive drug developers, this capital commitment highlights the escalating premium placed on next-generation targeted delivery platforms. As major drug manufacturers seek to replenish their commercial pipelines, specialized biotechnology startups demonstrating alternative cellular disruption techniques will likely remain prime targets for high-value industry consolidation.
About GlobeNewsInfo
GlobeNewsInfo.com is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.